The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.
Pfizer is aiming to be first on the grid in the race to being a vaccine against respiratory syncytial virus (RSV) to market, after reporting results from a phase 3 trial of the jab in older
Jack Torrance, investment specialist for Baillie Gifford's Health Innovation Fund, tells us how the organisation ensures its investments will have the most significant positive impact on al
The UK's Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna's bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults.
The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.